Honey Shows Protective and Therapeutic Effects Against Pancreatic Cancer in Rat Study

Pancreatic cancer remains one of the most lethal malignancies in human medicine, and the search for new preventive and therapeutic strategies has pushed researchers toward unexpected corners of the natural world. In a study published in BMC Complementary Medicine and Therapies, a team of Turkish surgeons and scientists from institutions including Elmalı State Hospital, Gaziantep Islamic Science and Technology University, the University of Health Sciences, and Necmettin Erbakan University report that a specific variety of honey, harvested from the flowers of Quercus pyrenaica, appears to blunt the earliest stages of pancreatic tumor development in a laboratory rat model. The findings, while preliminary, add to a growing body of literature suggesting that honey is far more than a sweetener, carrying a complex biochemical payload that may interfere with carcinogenesis.

The research, led by first author Ahmet Kılınç of the General Surgery Department at Elmalı State Hospital in Antalya, with corresponding author Mehmet Eşref Ulutaş and colleagues including Çiğdem Damla Deniz, Haydar Öztaş, İsmail Hasırcı, and Adil Kartal, was designed to test honey in two distinct modes: prophylaxis and therapy. Rather than studying established, late-stage tumors, the investigators focused on the very beginning of the disease process, when pancreatic tissue first begins to drift toward malignancy. This choice matters because pancreatic cancer is usually diagnosed late, and any intervention that could act at the precursor stage would be of enormous clinical interest if it could ever be translated to humans.

To model the disease, the team used the azaserine-rat model, a well-established experimental system in pancreatic cancer research. Azaserine is a chemical carcinogen that, when administered to rats, reliably induces lesions in the pancreas that mirror the early steps of human pancreatic tumor formation. The key structures the researchers tracked are called atypical acinar cell foci, or AACF, which are microscopic clusters of abnormal acinar cells regarded as precursor lesions of pancreatic cancer. Because these foci appear early, are quantifiable under the microscope, and correlate with later tumor burden, they serve as sensitive surrogate endpoints for chemoprevention studies, allowing researchers to measure an intervention’s effect long before overt tumors would develop.

The experimental design divided the animals into five groups: a control group, a honey-only group, an azaserine group that received the carcinogen alone, a therapeutic group, and a prophylactic group. The distinction between the last two is central to the study’s message. In the prophylactic group, honey was administered at the same time as azaserine, testing whether the substance could protect pancreatic tissue while it was being assaulted by the carcinogen. In the therapeutic group, honey was started three weeks after azaserine administration, a delay designed to simulate a more clinically realistic scenario in which the disease process is already underway before treatment begins. After eleven weeks of follow-up, the animals were sacrificed and their pancreatic tissues removed for detailed histopathological examination.

The quantitative readout of the study was rigorous. The researchers did not simply report whether lesions were present or absent; they measured three separate morphometric parameters of the atypical acinar cell foci. The first was the number of focus intersections per unit area, essentially a density measure of how many precursor lesions were packed into a given region of pancreatic tissue. The second was the ratio of the total AACF size to the size of the whole pancreas, capturing how much of the organ had been overtaken by abnormal cells. The third was the estimated number of foci per unit volume, a stereological estimate that corrects for the fact that a two-dimensional tissue section underestimates three-dimensional lesion burden. Together, these metrics provide a multidimensional picture of how extensively the carcinogen had transformed the pancreas in each group.

The results were consistent across both intervention arms. In the prophylactic group, all three quantitative measures of AACF were significantly lower than in the azaserine-only group, with statistical significance reported at p < 0.05. Critically, the therapeutic group, in which honey was introduced only after the carcinogenic process had been initiated, showed the same pattern of significant reduction. This means the honey did not merely shield healthy tissue from damage; it also appeared to slow or partially reverse the progression of lesions that had already begun to form. In parallel, the researchers compared serum levels of cancer antigen 19-9, the most widely used clinical biomarker for pancreatic cancer, and C-reactive protein, a general marker of inflammation, across the groups, adding a biochemical dimension to the histological findings.

What might explain such an effect? Honey is not a single compound but a chemically intricate matrix containing hundreds of substances, including polyphenols, flavonoids, hydrogen peroxide generated by the enzyme glucose oxidase, methylglyoxal, organic acids, and trace elements. Many of these constituents have documented antioxidant and anti-inflammatory activities in laboratory systems, and oxidative stress and chronic inflammation are recognized drivers of pancreatic carcinogenesis. Quercus pyrenaica honey, derived from an oak species native to parts of Europe and Anatolia, may possess a particularly favorable composition of these bioactive molecules, although the study did not perform a full chemical characterization of the honey used. The authors are careful to frame their work as a foundation for further investigation rather than a demonstration of mechanism.

The study’s limitations are those inherent to any animal experiment. The azaserine model, while valuable, does not recapitulate every feature of human pancreatic ductal adenocarcinoma, the most common and deadliest form of the disease in patients. Doses, timing, and species differences all complicate extrapolation to human beings, and the eleven-week follow-up window captures precursor lesions rather than invasive cancer or survival outcomes. The authors themselves acknowledge that their conclusions will gain real significance only if supported by clinical studies in this field. There is also the practical question of standardization: honey varies enormously by floral source, season, and geography, so any future therapeutic application would require rigorous quality control of the active constituents.

Nevertheless, the dual prophylactic and therapeutic signal is what makes the study notable. Many candidate chemopreventive agents show protection only when given before carcinogen exposure, a scenario with little clinical relevance, since people at risk of pancreatic cancer cannot usually be identified early enough. Demonstrating an effect when treatment begins after tumor initiation suggests that the bioactive components of Quercus pyrenaica honey may influence processes such as cell proliferation, apoptosis, or inflammation within already-transformed tissue, not just antioxidant shielding of healthy cells. If subsequent work identifies the responsible compounds and their molecular targets, it could open a path toward standardized extracts rather than raw honey as an intervention.

The research, which received ethics approval from the KONÜDAM Animal Ethics Committee of Necmettin Erbakan University and was conducted in accordance with the Declaration of Helsinki, was published open access with no external funding and no declared competing interests. For now, the message for the public is one of cautious fascination rather than immediate action: no one should interpret these findings as a reason to self-treat with honey, and patients with pancreatic disease should continue to rely on evidence-based oncological care. But the study adds a compelling data point to the argument that natural products deserve systematic scientific scrutiny, and it demonstrates that even a substance as ancient and familiar as honey can still surprise researchers when put to a properly controlled experimental test.

Subject of Research: Anti-tumoral effects of Quercus pyrenaica honey in an experimental rat model of pancreatic cancer

Article Title: Investigation of the anti-tumoral effect of honey in experimental pancreatic cancer

Article References: Kılınç, A., Ulutaş, M. E., Deniz, Ç. D., Öztaş, H., Hasırcı, İ., & Kartal, A. (2026). Investigation of the anti-tumoral effect of honey in experimental pancreatic cancer. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05565-2

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05565-2

Keywords: honey, pancreatic cancer, Quercus pyrenaica, azaserine rat model, atypical acinar cell foci, CA 19-9, C-reactive protein, chemoprevention, experimental oncology, natural products, complementary medicine, preclinical research